Next Gen Targeted nanoparticles for Inhibiting Gli2 in Bone Metastatic Tumors
用于抑制骨转移肿瘤中 Gli2 的下一代靶向纳米颗粒
基本信息
- 批准号:10623705
- 负责人:
- 金额:$ 66.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-01 至 2027-05-31
- 项目状态:未结题
- 来源:
- 关键词:Academic Medical CentersAcrylatesAffectAlendronateAllograftingBiodistributionBiological AvailabilityBiologyBiomedical EngineeringBone DensityBone DiseasesBone MarrowBone PainBone ResorptionBone necrosisBone neoplasmsBreastBreast Cancer CellCancer BiologyCancer ModelCell modelChemistryChemoresistanceClinicalCollecting CellDataDevelopmentDiseaseDisseminated Malignant NeoplasmDoseDose LimitingDrug KineticsDrug ScreeningEnsureEquilibriumFamilyFormulationFractureGenerationsGeneticGlycolsGoalsGrantGrowthGrowth FactorHematologyHistopathologyHomeostasisHumanHydrophobicityHypercalcemiaImmunocompetentJawKineticsLeadLigand BindingLiverLocationMalignant neoplasm of lungMaximum Tolerated DoseMedicineMetastatic Neoplasm to the BoneMetastatic breast cancerMethodsMicrometastasisModelingModificationMorbidity - disease rateNeoplasm MetastasisOncologyOsteoblastsOsteoclastsPaclitaxelPainPatient-Focused OutcomesPatientsPharmacodynamicsPharmacologyPolymer ChemistryPolymersPositioning AttributePre-Clinical ModelPreclinical TestingPrimary NeoplasmPrincipal InvestigatorProliferatingPropertyProstateReactive Oxygen SpeciesRepressionRunningSerum MarkersSiteStainsSubgroupSulfidesSystemTechnologyTestingToxic effectTranslationsTumor BurdenTumor Cell InvasionTumor ExpansionUniversitiesUp-RegulationWomanWorkZoledronic Acidantagonistbisphosphonatebonecancer stem cellchemotherapyclinical translationclinically relevantcookingdesigndrug candidatedrug efficacyeffective therapyefficacy evaluationefficacy studyexperienceimprovedin vivoinhibitorintravenous administrationintravenous injectionmalignant breast neoplasmmetastatic processmouse modelnanoparticleneoplastic cellnephrotoxicitynovelnovel therapeuticsparathyroid hormone-related proteinparticlepharmacokinetics and pharmacodynamicspre-clinicalpropyleneprotein expressionresearch clinical testingside effectskeletalskeletal-related eventssmall moleculesmall molecule inhibitorstandard of caresystemic toxicitytranscription factortreatment effecttumortumor growthvalidation studies
项目摘要
Despite progress in the treatment of primary tumors, metastatic disease remains incurable. While all metastatic
sites are important clinically, skeletal metastases are common in patients with breast, prostate, lung cancer,
and other, with approximately 70% of women that die from metastatic breast cancer experiencing serious
complications from bone metastases. Once established in the bone, tumors disrupt normal bone homeostasis
leading to increased pain, fracture, and general morbidity. Our previous work has established the transcription
factor Gli2 as a promising target for reducing tumor induced bone disease. After identifying the small molecule
inhibitor, Gli Antagonist 58 (GANT58), as a promising inhibitor of Gli2 activity in bone metastatic tumors, we
discovered the poor bioavailability of GANT58 limited its use in systemic delivery models. Thus, we developed
polymeric NPs to solubilize, improve the pharmacokinetics (PK), and promote bioavailability of GANT58
(GANT58-NPs). The NPs comprised reactive oxygen species (ROS)-responsive poly(propylene sulfide-block-
oligoethylene glycol acrylate) (PPS-b-POEGA). Intravenous injection of the 1st generation GANT58-NPs
(Dh=93 nm) reduced TIBD in models of intratibial and intracardiac breast tumor cell inoculation and in a lung
cancer model (3 unique models). GANT58-NPs were safe (did not elevate serum markers of liver/kidney
toxicity or cause detectable histopathology. Our 2nd generation NPs were bone targeted (BT-GANT58-NPs),
and the chemistry utilized enabled tuning of the density of the bone binding ligand, alendronate (ALN), a
bioactive bisphosphonate (osteoclast inhibitor). While both formulations reduced tumor invasion into bone and
reduced tumor proliferation by ki67 staining, they did not eliminate tumor and did not significantly reduce tumor
bulk in models of established bone metastatic disease. Here, we propose to screen a broader polymer
chemistry space focusing on: (1) Developing an alternative bone targeting strategy without inherent bioactivity;
(2) Studying how NP core chemistry affects GANT58 loading, GANT58 triggerable release, and consequent in
vivo PK; (3) Defining the maximum tolerated dose (MTD), dose-limiting toxicities, and dose dependent PK /
PD. In addition, we will evaluate the efficacy of a co-loaded GANT58 and paclitaxel BT-NP formulation. Each of
these formulations will be evaluated for detailed PK/PD and biodistribution properties to identify promising
formulations to reduce tumor induced bone disease without inducing systemic toxicity. Our preliminary data
show promising results that include low toxicity and efficacy in reducing tumor burden in bone and bone
destruction. This proposal will explore the efficacy and PK/PD properties in more detail to develop a promising
therapy for eventual translation. The results of these studies will help identify a novel and promising strategy to
reduce tumor burden and bone destruction in patients with bone metastatic disease. Due to the current lack of
effective therapies for these patients, the results of these studies could impact patient outcomes and lead to
exciting new therapies for patients with bone metastatic tumors.
尽管原发性肿瘤的治疗取得了进展,但转移性疾病仍然无法治愈。而所有的转移
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Craig Lewis Duvall其他文献
Craig Lewis Duvall的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Craig Lewis Duvall', 18)}}的其他基金
Tissue Adhesive RNA Interference Nanoparticles to Block Progression of Posttraumatic and Spontaneous Osteoarthritis.
组织粘附 RNA 干扰纳米颗粒可阻止创伤后和自发性骨关节炎的进展。
- 批准号:
10539405 - 财政年份:2022
- 资助金额:
$ 66.79万 - 项目类别:
Tissue Adhesive RNA Interference Nanoparticles to Block Progression of Posttraumatic and Spontaneous Osteoarthritis.
组织粘附 RNA 干扰纳米颗粒可阻止创伤后和自发性骨关节炎的进展。
- 批准号:
10688080 - 财政年份:2022
- 资助金额:
$ 66.79万 - 项目类别:
Albumin hitchhiking siRNAs for gene targeting in aged brain
白蛋白搭便车 siRNA 用于老年大脑基因靶向
- 批准号:
10611521 - 财政年份:2022
- 资助金额:
$ 66.79万 - 项目类别:
Albumin hitchhiking siRNAs for gene targeting in aged brain
白蛋白搭便车 siRNA 用于老年大脑基因靶向
- 批准号:
10467737 - 财政年份:2022
- 资助金额:
$ 66.79万 - 项目类别:
Albumin Binding siRNAs for Systemic Treatment of Multi-Joint Osteoarthritis
白蛋白结合 siRNA 用于多关节骨关节炎的全身治疗
- 批准号:
10358582 - 财政年份:2021
- 资助金额:
$ 66.79万 - 项目类别:
Hybrid Synthetic and Biologic Shear Thinning Hydrogels for Diabetic Wound Healing
用于糖尿病伤口愈合的混合合成和生物剪切稀化水凝胶
- 批准号:
10446305 - 财政年份:2021
- 资助金额:
$ 66.79万 - 项目类别:
Hybrid Synthetic and Biologic Shear Thinning Hydrogels for Diabetic Wound Healing
用于糖尿病伤口愈合的混合合成和生物剪切稀化水凝胶
- 批准号:
10245000 - 财政年份:2019
- 资助金额:
$ 66.79万 - 项目类别:
Hybrid Synthetic and Biologic Shear Thinning Hydrogels for Diabetic Wound Healing
用于糖尿病伤口愈合的混合合成和生物剪切稀化水凝胶
- 批准号:
10668940 - 财政年份:2019
- 资助金额:
$ 66.79万 - 项目类别:
Hybrid Synthetic and Biologic Shear Thinning Hydrogels for Diabetic Wound Healing
用于糖尿病伤口愈合的混合合成和生物剪切稀化水凝胶
- 批准号:
10005338 - 财政年份:2019
- 资助金额:
$ 66.79万 - 项目类别:
MK2 Inhibitory Nanoplexes to Enhance Long-Term Vascular Graft Patency
MK2 抑制性纳米复合物可增强血管移植物的长期通畅性
- 批准号:
9463239 - 财政年份:2016
- 资助金额:
$ 66.79万 - 项目类别:
相似海外基金
Development of Catalytic Green Method to Synthesize Alkyl Acrylates and Oligopeptides
催化绿色合成丙烯酸烷基酯和寡肽的方法研究进展
- 批准号:
20K20559 - 财政年份:2020
- 资助金额:
$ 66.79万 - 项目类别:
Grant-in-Aid for Challenging Research (Pioneering)
Synthesis of Reactive Polymer by Ring-Opening and -Expansion of Cyclic Acrylates with Dynamic Ring-Structure
具有动态环结构的环状丙烯酸酯开环扩链合成反应性聚合物
- 批准号:
16K05792 - 财政年份:2016
- 资助金额:
$ 66.79万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Silicone elastomers through reductive silylation of acrylates.
通过丙烯酸酯的还原硅烷化形成有机硅弹性体。
- 批准号:
480575-2015 - 财政年份:2015
- 资助金额:
$ 66.79万 - 项目类别:
University Undergraduate Student Research Awards
Mechanistic Studies of the BINOL-Tin Tetrachloride-Catalyzed Formal [3 + 2] Cycloaddition of Indoles and Acrylates
BINOL-四氯化锡催化缩甲醛[3 2]吲哚与丙烯酸酯环加成反应的机理研究
- 批准号:
404205-2011 - 财政年份:2013
- 资助金额:
$ 66.79万 - 项目类别:
Postgraduate Scholarships - Doctoral
Mechanistic Studies of the BINOL-Tin Tetrachloride-Catalyzed Formal [3 + 2] Cycloaddition of Indoles and Acrylates
BINOL-四氯化锡催化缩甲醛[3 2]吲哚与丙烯酸酯环加成反应的机理研究
- 批准号:
404205-2011 - 财政年份:2012
- 资助金额:
$ 66.79万 - 项目类别:
Postgraduate Scholarships - Doctoral
Mechanistic Studies of the BINOL-Tin Tetrachloride-Catalyzed Formal [3 + 2] Cycloaddition of Indoles and Acrylates
BINOL-四氯化锡催化缩甲醛[3 2]吲哚与丙烯酸酯环加成反应的机理研究
- 批准号:
404205-2011 - 财政年份:2011
- 资助金额:
$ 66.79万 - 项目类别:
Postgraduate Scholarships - Doctoral
Regioselective Mizoroki-Heck reactions at-position of acrylates
丙烯酸酯位点区域选择性 Mizoroki-Heck 反应
- 批准号:
21550108 - 财政年份:2009
- 资助金额:
$ 66.79万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Miniemulsification of acrylates for latex production
用于乳胶生产的丙烯酸酯微乳化
- 批准号:
366419-2008 - 财政年份:2008
- 资助金额:
$ 66.79万 - 项目类别:
University Undergraduate Student Research Awards
US-Turkey Cooperative Research: Functionalized Acrylates with Tailored Properties and Applications
美国-土耳其合作研究:具有定制特性和应用的功能化丙烯酸酯
- 批准号:
0218222 - 财政年份:2002
- 资助金额:
$ 66.79万 - 项目类别:
Continuing Grant














{{item.name}}会员




